Resilience (National Resilience), a biomanufacturing company, acquired Ology Bioservices (Ology Bio), a privately held company that reportedly also specializes in biologic drug substance manufacturing from early stage through commercial products.
Ology Bio, based in Alachua, FL, develops and manufactures drugs and biologics for commercial customers as well as the US government, with more than $1.8 billion in government contracts awarded. The acquisition provides Resilience with 300 skilled employees as well as more than 200,000 square feet of manufacturing, office, process development, quality assurance, and quality control space across locations in Florida, California, and Maryland, with additional expansion projects underway, according to Rahul Singhvi, ScD, CEO of Resilience.
“This acquisition gives us additional resources and capabilities as we continue on our mission of broadening access to complex medicines, protecting biopharmaceutical supply chains, and strengthening preparedness,” said Singhvi.
Ology Bio’s infrastructure will provide services for Resilience’s customers, including regulatory support from preclinical through licensure, clinical trial operational support and bioanalytical testing, as well as cGMP manufacturing up to Biosafety Level 3 (BSL3), continued Singhvi, adding that Ology Bio’s manufacturing capabilities include cell and gene therapies, live viral vaccines and vectors, oncolytic viruses, plasmids, and monoclonal antibodies.
In November, Ology was awarded a $37 million contract by the U.S. Department of Defense to develop an advanced anti-COVID-19 monoclonal antibody cocktail. The contract also included supporting the DOD with a request for an Emergency Use Authorization and/or Expanded Access of the monoclonal antibody cocktail for at-risk military personnel.
